Hotgen's invested company has obtained domestic Class III medical device registration certificate

Hotgen's affiliated company Hangzhou Aorui Biotechnology Co., Ltd. has obtained the domestic Class III medical device registration certificate. The product is a gene methylation detection kit, suitable for the in vitro qualitative detection of methylation of multiple genes in human plasma, primarily used for assisting in the diagnosis of suspected primary liver cancer

Beijing Hotgen Biotech Q3 net loss at 25.0 million yuan

Beijing Hotgen Biotech Q3 net loss at 25.0 million yuan

Hotgen released its performance for the first three quarters, with a net loss attributable to the parent company of 109 million yuan

According to the Zhitong Finance APP, Hotgen disclosed its third-quarter report for 2025. The company achieved revenue of 310 million yuan in the first three quarters, a year-on-year decrease of 19.8%; the net loss attributable to shareholders of the listed company was 109 million yuan; the net profit excluding non-recurring items was a loss of 148 million yuan; basic earnings per share were -1.23 yuan

Hotgen's invested company SGC001's innovative drug Phase Ib clinical trial has obtained positive preliminary results

Hotgen announced that its affiliated company ShunJing Pharmaceutical's innovative drug SGC001 has achieved positive preliminary results in Phase Ib clinical research. The study shows that in patients with anterior ST-segment elevation myocardial infarction receiving PCI treatment, SGC001 demonstrated an effective trend in myocardial protection in the 600mg and 900mg dosage groups compared to the placebo group, with a significant reduction in the percentage of myocardial infarction area (IS%) and a shorter time for high-sensitivity cardiac troponin I and high-sensitivity C-reactive protein to return to normal. The project will continue to advance according to the clinical trial protocol

The concept of innovative drugs has rebounded, with Chimin gaining 6 limit-ups in 12 days, Staidson BioPharm rising over 7%, Hotgen increasing over 5%, and stocks like Medicilon, Cosunter, and BrightGene also seeing gains